Lantheus price target lowered to $122 from $127 at B. Riley

B. Riley lowered the firm’s price target on Lantheus (LNTH) to $122 from $127 and keeps a Buy rating on the shares. Competitor Telix’s (TLX) Gozellix received FDA approval for the next-generation PSMA-PET imaging agent for prostate cancer, and the firm will closely watch the market-share dynamics after the pass-through expiration of Illuccix on June 30, and the commercial ramp-up of Gozellix in the second half of 2025 after pass-through status is granted, the analyst tells investors in a research note. B. Riley remains confident that Lantheus can deliver growth of Pylarify in 2025 and meet the low-single to mid-single digit growth guidance.